Biopharma Congress V | Friends of Cancer Research

You are here

Biopharma Congress V

BIOPHARMA CONGRESS V
Monday, October 7, 2019

8:00AM - 5:00PM


PRESENTED BY PREVISION POLICY + FRIENDS OF CANCER RESEARCH


Gene Therapies. New Payment Models. FDA Approval Standards. 


2019 CONFIRMED SPEAKERS
SCOTT GOTTLIEB (AEI)

JOHN O'BRIEN (HHS)

AMY HALL (HOUSE WAYS & MEANS COMMITTEE)

 

For more information, please Click HERE and scroll through below for the full agenda.

 

FDA Past, Present, and Future: A Conversation with Former FDA Commissioner Scott Gottlieb (8:15am-9:00am)

  • Prevision Policy’s Michael McCaughan (Moderator)

 

Drug Pricing Options Under Single Payer (9:00am-10:15am)

  • Johnson & Johnson VP Global Market Access and RWE Christoph Glaetzer
  • House Ways & Means Health Subcommittee Majority Staff Director Amy Hall
  • ICER Founder and President Steve Pearson
  • Patients For Affordable Drugs Founder and President David Mitchell
  • Manatt Health Solutions Advisor Ian Spatz (Moderator)

 

Prescription Drugs and Domestic Policy (10:20 am-10:40am)

  • White House Domestic Policy Council Director Joe Grogan
  • Prevision Policy’s Ramsey Baghdadi (Moderator)

 

Break (10:40am-11:00am)

 

A Center Leadership Perspective: CDER, CBER, and OCE (11:00am-12:00pm)

  • CDER Director Janet Woodcock
  • CBER Director Peter Marks
  • OCE Deputy Director Gideon Blumenthal
  • Friends of Cancer Research Chairperson and Founder Ellen Sigal (Moderator)

 

Lunch Keynote: Acting FDA Commissioner Ned Sharpless

 

Regulating the Third Era Of Drug Development: Individualization (1:30pm-2:30pm)

  • CBER Office of Tissues and Advanced Therapies Director Wilson Bryan
  • Lilly Oncology Product Team Leader Symantha Melemed
  • OCE Deputy Director Paul Kluetz
  • Amgen SVP-Global Development Elliott Levy
  • Duke-Margolis Senior Policy Fellow Rachel Sherman
  • Prevision Policy’s Cole Werble (Moderator)

 

Break: (2:30pm-2:50pm)

 

Subscriptions, Installments, and Indexing: Drug Payment In 2020 (2:50pm-3:50pm)

  • Gilead Executive Director of Public Policy Rekha Ramesh
  • Blue Cross Blue Shield Director For Cellular Immunotherapy And Gene Therapy Stephanie Farnia
  • Former HHS Senior Advisor for Drug Pricing Reform John O’Brien
  • Spark Therapeutics Head of Government Affairs Jeremy Allen
  • ADVI Founder and CEO Marc Samuels (Moderator)

 

FDA Rising Stars Panel (3:50pm-5:00pm)

  • Office of Hematology & Oncology Products/Division of Oncology Products 2 Associate Director Steven Lemery
  • Division of Psychiatry Products Acting Director Tiffany Farchione
  • Division of Bone, Reproductive & Urologic Products Director Hylton Joffe
  • CDER Deputy Director for Clinical Science Bob Temple
  • Prevision Policy’s Kate Rawson (Moderator)
Date: 
Monday, October 7, 2019 -
8:00am to 5:00pm
Event Type: